Devices/Recall·openFDA/device

Boston Scientific Corporation — Class II: Rapid Refill Continuous Injection System, UPN M00566001

MediumPublished Jul 22, 2026· AI-analyzed Jul 27, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Boston Scientific Corporation has initiated a Class II recall for its Rapid Refill Continuous Injection System (UPN M00566001) because the system includes a recalled Medline Namic Angiographic Control Syringe. These syringes may loosen or disconnect from the manifold, causing fluid leakage, aspiration issues, or procedural delays.

Who it affects

Boston Scientific Corporation and clinical sites utilizing the Rapid Refill Continuous Injection System. Functional impacts extend to surgical staff, supply chain managers, and quality compliance officers.

Why it matters

This recall highlights the significant risk of secondary impacts when a third-party component is integrated into a larger system. The failure mode—disconnection from the manifold—poses direct risks to procedural efficiency and patient safety through potential air embolism or blood loss during angiography. This suggests that firms relying on sub-assemblies must maintain robust tracking to respond quickly to supplier-level enforcement actions.

Practical takeaway

Inventory teams should immediately identify and sequester affected UPN M00566001 units. Regulatory and QA departments should review supplier quality agreements and component change notification processes to ensure upstream recalls are identified and addressed promptly.

FDA source material

Class II. Reason: Devices contain recalled Medline Namic Angiographic Control Syringe with Rotating Adaptor. There is a risk of syringe loosening or disconnecting from the manifold, resulting in loose connection or complete disconnection. May lead to difficulty connecting syringe, inability to aspirate or inject properly, fluid leakage, or separation of the syringe from the system, potentially requiring device exchange and prolonging the procedure.. Product: Rapid Refill Continuous Injection System, UPN M00566001. Firm: Boston Scientific Corporation (Marlborough MA United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.